Hematological Cancer Cell Lines & Primary Cells from Patients

myeloma cell

Panel of Unique Myeloma Cell Lines

Diag2tec has a unique large collection of Human Myeloma Cell Lines (HMCLs, n=40) including 25 cell lines derived from MM patients from Montpellier hospital and dependent on exogenous IL-6 for growing and survival. The latter stop cell cycling and enter apoptosis after removal of exogenous cytokines and constitute a relevant model to study the function of drugs and underlying drug resistance mechanisms. We previously demonstrated that cell lines are representative of the molecular heterogeneity described in patients with 6 different molecular subgroups (publication and patent here).

We have characterized our MM cell lines collection using RNA seq, Exome Seq, CHIP seq (6 histone marks), DNA methylation, SNP and Affymetrix GEP. In addition, immunophenotypic and cytogenetic characterization of all HMCLs has been carried out. Moreover, we have also characterized the HMCLs response to 20 molecules/drugs (melphalan, lenalidomide, pomalidomide, bortezomib, carfilzomib, cell cycle inhibitor, kinases inhibitors, HDACi, DNMTi, EZH2 inhibitor, DNA repair inhibitors…), (see publications and patents here).

We have also derived human myeloma cell lines resistant to Proteasome inhibitors, IMiDs, Dexamethasone, Melphalan and, HDACi (publication in revision).

With these fully characterized cell lines, Diag2Tec offers you the possibility to screen our anti-myeloma drugs, to investigate the drug resistance and associated mechanisms of action of your specific molecule.

Go to associated services

In a recent study, we present for the first time the mutational landscape of human myeloma cell lines. We conducted whole-exome sequencing (WES) on 30 HMCLs and we identified mutations in genes involved in key pathways in MM and mutations known as associated with drug resistance. This publication confirms the interest of our cell lines to study the mechanism of resistance of therapeutic agent in MM and to identify new biomarkers to predict the response of cancer cells. (publication here)

Other Hematological Cell Lines

Diag2tec has also a collection of human Diffuse Large B Cell Lymphoma (DLBCL) cell lines (n=20) and a collection of Acute Myeloid Leukemia (AML) cell lines (n=10).

We have characterized our panel of DLBCL cell lines to 15 legitimate drugs. We have also fully characterized these cell lines using microarray and RNA Seq technologies.

Please contact us for more information

Other hematological cell lines

Primary Hematological Cells

Diag2tec accesses to a large bank of primary Multiple Myeloma Cells. We have a strong expertise in the purification and culture of primary MM cells (MMCs) with the bone marrow microenvironment cells.

Diag2Tec also access to a wide bank of primary samples of patients from other hematological malignancies (B and T lymphomas, leukemias, myelodysplastic syndromes…).

Additionally, we accesses to the clinical response of the associated patients (response to conventional treatments at diagnosis and relapsed used in Montpellier hospital), to the DNA or RNA of samples and to the plasma associated.

For some samples, we have also purified tumoral plasma cell and characterized genomic profiles (DNA array, RNA seq, Exome seq).

Go to associated services

Based on this model of choice, we offer you a large range of services to investigate the effect of your specific therapeutic agent in the biology of MM

Diag2Tec’s Headquarters

Diag2Tec
Cap Omega, Rond-Point Benjamin Franklin
CS 39521
34960 Montpellier, France
Email: contact@diag2tec.com